pharmaceuticals

Defining the limits of immunotherapy in early small-cell lung cancer

by

Immunotherapy Plateau? New Data Shifts Focus Back to Radiation in Small Cell Lung Cancer A recent international clinical trial, NRG-LU005, has delivered a nuanced message in the fight against limited-stage small cell lung cancer (LS-SCLC). While the addition of immunotherapy drug atezolizumab to standard chemoradiation didn’t significantly improve overall survival, a surprising trend emerged: twice-daily … Read more

Ron Johnson Investigates FDA Rejections of Rare Disease Treatments

by

FDA Under Scrutiny: A Potential Shift in Rare Disease Drug Approvals Senator Ron Johnson (R-Wis.) has launched an investigation into the Food and Drug Administration’s (FDA) rejections of treatments for rare diseases, signaling growing concern over the agency’s decision-making process. The senator is specifically requesting access to the complete response letters – official rejections – … Read more

FDA’s Vinay Prasad Resigns: A Controversial Exit Explained

by

FDA Vaccine Chief’s Exit Signals a Potential Shift in Regulatory Scrutiny The recent departure of Dr. Vinay Prasad, the Food and Drug Administration’s (FDA) vaccine chief, marks a potentially significant moment for the agency and the pharmaceutical industry. Prasad’s second exit from the FDA, confirmed on March 6, 2026, follows a period of controversial decisions … Read more

Reviva Pharmaceuticals Announces Major Share Consolidation Plan

by

Reviva, Pharmaceuticals 07.03.2026 – 01:28:22 | boerse-global.de Reviva Pharmaceuticals enacts a 1-for-20 reverse stock split to boost share price for Nasdaq compliance and attract institutional investors, effective March 9. Reviva Pharmaceuticals Holdings Inc. (RVPH) is implementing a 1-for-20 reverse stock split, effective at the market open on Monday, March 9. Navigating Reverse Stock Splits: A … Read more

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

by

Inovio Pharmaceuticals Investors Face Deadline in Securities Class Action Investors who purchased Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, may be eligible to participate in a securities class action lawsuit. A lead plaintiff deadline of April 7, 2026, has been set for those wishing to direct the litigation. … Read more

Battle to get ‘female Viagra’ to market — and how ‘Grey’s Anatomy’ played a role

by

The Ongoing Quest for Female Sexual Wellness: Beyond the “Pink Pill” For decades, pharmaceutical solutions for male sexual dysfunction, like Viagra and Cialis, have been readily available. Yet, a comparable option for women has been a more elusive goal. Now, a new documentary, “The Pink Pill: Sex, Drugs & Who Has Control,” premiering on Paramount+, … Read more

Eli Lilly launches program to boost employer coverage of obesity drugs

by

Lilly’s New Playbook: Expanding Access to Obesity Drugs and Reshaping the Market Eli Lilly has launched “Employer Connect,” a new platform aimed at making its obesity drug, Zepbound, more accessible to employees through their health insurance. This move addresses a significant hurdle in the rapidly evolving obesity treatment landscape: cost and inconsistent employer coverage. Although … Read more

Gene-modified pancreas cells offer hope for people with type 1 diabetes

by

Gene Editing and the Future of Pancreas Transplants: A Fresh Hope for Type 1 Diabetes Four weeks after transplanting genetically modified insulin-producing cells into a patient with type 1 diabetes, researchers at Uppsala University Hospital achieved a breakthrough: the transplanted cells were alive and functioning, despite the patient not taking any immune-system-suppressive drugs. This marks … Read more

Global breast cancer burden rising fastest in low-income countries

by

Breast Cancer Cases Projected to Surge Globally: A Looming Health Crisis Despite advancements in treatment, a new analysis from the Global Burden of Disease Study Breast Cancer Collaborators paints a concerning picture: global breast cancer cases are predicted to increase by a third, rising from 2.3 million in 2023 to over 3.5 million in 2050. … Read more

Trump’s Drug Price Deals: 3-Year Limit Revealed | STAT

by

Trump’s Drug Pricing Deals: A Three-Year Window for Change? President Trump’s push for lower prescription drug prices, often touted through “most-favored nation” (MFN) deals with pharmaceutical companies, continues to be a subject of scrutiny. Recent Securities and Exchange Commission (SEC) filings reveal a key detail previously undisclosed: at least some of these agreements are set … Read more

© 2026 Newsy Today. All rights reserved.


For contact, advertising, copyright, issues email: [email protected]

For contact, advertising, copyright, issues email: [email protected]